ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use—and possibly Europe

With a trial win in certain acute myeloid leukemia (AML) patients, Servier’s cancer med Tibsovo is primed to break into front-line use as a combo treatment for patients who can't handle intensive chemotherapy. Meanwhile, the drug may now have the data it needs to clinch an approval in Europe, a Servier executive said in a recent interview.